© 2026 Omnitheia. Privacy notice
For BIO-Europe 2026, Cologne
Validate your asset with the KOLs who will shape its adoption and the payers who will reimburse it.
Most licensing deals and funding rounds stall on assumptions nobody has tested. Omnitheia runs blinded KOL, HCP and payer research end to end and turns it into the evidence a partner or investor will accept.
Complimentary platform access for BIO-Europe attendees.
More about your trial
The Omnitheia platform will give you access to:
Real-World Intelligence
We conduct primary research continuously. The platform holds those insights, including original transcripts and verbatim from KOLs, HCPs and payers. Your team can search current real-world evidence directly, before commissioning research of its own. New research can be prioritised in your therapy areas.
Secondary Intelligence
Published data and competitive intelligence on demand, drawn from 100K ingested original documents and source APIs.
Analytics on your own documents
Add your own documents, transcripts and reports, held in your own environment behind enterprise-grade security. Primary research, secondary intelligence and your own material combine into a single report.
Controlled Claude
Claude, curated for life sciences, with controls and security in place. Omnitheia's control centre governs the sources the model draws on and validates its outputs.
Uploads stay in your own environment. We do not access them, and they never enter the public domain. Guardrails restrict the model to validated original documents and source APIs, not the open internet. Built-in quality control validates outputs against source, and verbatim stays unchanged.
Market leading methodology
One process, three phases
We run PMR end to end. No handoff between an expert network that recruits and a separate team that does the research.
1
Pre-researchIn-house advisors and AI build the discussion guides, briefings and screeners before the first interview is booked.
2
During researchWe recruit and run the interviews ourselves, through our advisory board and vetted global partners, with compliance and support included.
3
Post-researchWe turn verbatim into licensing-grade analysis: what it changes about the price, the population and the risk. Then query all qualitative and quantitative data and build custom reports across primary research, our BI data and your own documents.
The trial
Book your complimentary trial
Complimentary platform access for BIO-Europe attendees.